Stocktoria
AMGEN INC AMGN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1983-06-17
AMGEN INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36.8B | $33.4B | $28.2B | $26.3B | $26.0B |
| SG&A expense | $7.0B | $7.1B | $6.2B | $5.4B | $5.4B |
| Operating income | $9.1B | $7.3B | $7.9B | $9.6B | $7.6B |
| Income tax | $1.3B | $519.0M | $1.1B | $794.0M | $808.0M |
| Net income | $7.7B | $4.1B | $6.7B | $6.6B | $5.9B |
| EPS (diluted) | $14.23 | $7.56 | $12.49 | $12.11 | $10.28 |
| Operating cash flow | $10.0B | $11.5B | $8.5B | $9.7B | $9.3B |
| Free cash flow | $8.1B | $10.4B | $7.4B | $8.8B | $8.4B |
| Cash & equivalents | $9.1B | $12.0B | $10.9B | $7.6B | $8.0B |
| Inventory | $6.2B | $7.0B | $9.5B | $4.9B | $4.1B |
| Total assets | $90.6B | $91.8B | $97.2B | $65.1B | $61.2B |
| Shareholders' equity | $8.7B | $5.9B | $6.2B | $3.7B | $6.7B |
Source: SEC EDGAR filings · CIK 0000318154 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.